不同驱动基因突变 IV 期 NSCLC 如何治疗？最新版 ASCO 指南推荐要点总结

导语：ASCO 更新发布 2024.1 版驱动基因突变的 IV 期 NSCLC 患者生存指南。

声明：本材料由阿斯利康提供，仅供医疗卫生专业人士参考

审批编号：CN-141599  过期日期：2025-9-14

内容审核：nyh

项目审核：杨静

题图来源：图虫创意

参考文献

[1]Owen DH, Ismaila N, Freeman-Daily J, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1. J Clin Oncol. 2024;42(20):e44-e59.

[2]Jaiyesimi IA, Leighl NB, Ismaila N, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024 ;42(11):e23-e43.

[3]P. Janne, D. Planchard, Y. Cheng, et al. Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2). 2023 WCLC. Abstract PL03.13.